The prospective, muti-center clinical study to evulate the safety and effiency of cingularbio heart valve

Status

Active, not recruiting

Phases

Phase 3

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-16008380

Enrollment

Unknown

Registered

2016-04-27

Start date

2016-05-02

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart valve

Interventions

single arm:heart valve implantation

Eligibility

Sex/Gender

All

Age

60 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. older than 60, less than 85; 2. the NYHA is less than IV; 3. the indication is to heart valve replcement.

Exclusion criteria

Exclusion criteria: 1. experienced heart valved implantation; 2. more tricuspid valve or CABG needed; 3. active endocardium patients.

Design outcomes

Primary

Measure	Time frame
device related adverse events at 12 month;	—

Countries

China

Contacts

Public ContactDr. Wang Chunsheng

Zhongshan Hospital of Fudan University

hong.tao@zs-hospital.sh.cn+86 021 64041990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026